Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Share-based Compensation: 2014-2024

Historic Share-based Compensation for Editas Medicine (EDIT) over the last 11 years, with Dec 2024 value amounting to $21.4 million.

  • Editas Medicine's Share-based Compensation fell 53.60% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 47.71%. This contributed to the annual value of $21.4 million for FY2024, which is 8.18% up from last year.
  • Latest data reveals that Editas Medicine reported Share-based Compensation of $21.4 million as of FY2024, which was up 8.18% from $19.8 million recorded in FY2023.
  • Editas Medicine's 5-year Share-based Compensation high stood at $43.4 million for FY2021, and its period low was $19.8 million during FY2023.
  • Over the past 3 years, Editas Medicine's median Share-based Compensation value was $21.4 million (recorded in 2024), while the average stood at $23.5 million.
  • Per our database at Business Quant, Editas Medicine's Share-based Compensation skyrocketed by 87.42% in 2021 and then tumbled by 32.50% in 2022.
  • Yearly analysis of 5 years shows Editas Medicine's Share-based Compensation stood at $23.2 million in 2020, then surged by 87.42% to $43.4 million in 2021, then crashed by 32.50% to $29.3 million in 2022, then slumped by 32.42% to $19.8 million in 2023, then increased by 8.18% to $21.4 million in 2024.